PMID- 30556344
OWN - NLM
STAT- MEDLINE
DCOM- 20190902
LR  - 20190902
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
VI  - 20
IP  - 2
DP  - 2019 Mar
TI  - An improved clinical model to predict stimulated C-peptide in children with 
      recent-onset type 1 diabetes.
PG  - 166-171
LID - 10.1111/pedi.12808 [doi]
AB  - BACKGROUND: Stimulated C-peptide measurement after a mixed meal tolerance test 
      (MMTT) is the accepted gold standard for assessing residual beta-cell function in 
      type 1 diabetes (T1D); however, this approach is impractical outside of clinical 
      trials. OBJECTIVE: To develop an improved estimate of residual beta-cell function 
      in children with T1D using commonly measured clinical variables. 
      SUBJECTS/METHODS: A clinical model to predict 90-minute MMTT stimulated C-peptide 
      in children with recent-onset T1D was developed from the combined AbATE, START, 
      and TIDAL placebo subjects (n = 46) 6 months post-recruitment using multiple 
      linear regression. This model was then validated in a clinical cohort (Hvidoere 
      study group, n = 262). RESULTS: A model of estimated C-peptide at 6 months 
      post-diagnosis, which included age, gender, body mass index (BMI), hemoglobin A1c 
      (HbA1c), and insulin dose predicted 90-minute stimulated C-peptide measurements 
      (adjusted R(2)  = 0.63, P < 0.0001). The predictive value of insulin dose and 
      HbA1c alone (IDAA1c) for 90-minute stimulated C-peptide was significantly lower 
      (R(2 =) 0.37, P < 0.0001). The slopes of linear regression lines of the estimated 
      and stimulated 90-minute C-peptide levels obtained at 6 and 12 months post 
      diagnosis in the Hvidoere clinical cohort were R(2)  = 0.36, P < 0.0001 at 
      6 months and R(2)  = 0.37, P < 0.0001 at 12 months. CONCLUSIONS: A clinical model 
      including age, gender, BMI, HbA1c, and insulin dose predicts stimulated C-peptide 
      levels in children with recent-onset T1D. Estimated C-peptide is an improved 
      surrogate to monitor residual beta-cell function outside clinical trial settings.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Buchanan, Kerry
AU  - Buchanan K
AUID- ORCID: 0000-0001-7147-4631
AD  - The University of Queensland, Diamantina Institute, Translational Research 
      Institute, Brisbane, Queensland, Australia.
AD  - Queensland Children's Hospital, Department of Paediatric Endocrinology, 
      Queensland Children's Hospital, South Brisbane, Queensland, Australia.
FAU - Mehdi, Ahmed M
AU  - Mehdi AM
AD  - The University of Queensland, Diamantina Institute, Translational Research 
      Institute, Brisbane, Queensland, Australia.
FAU - Hughes, Ian
AU  - Hughes I
AD  - The University of Queensland, Mater Research Institute, Translational Research 
      Institute, Brisbane, Australia.
FAU - Cotterill, Andrew
AU  - Cotterill A
AD  - Queensland Children's Hospital, Department of Paediatric Endocrinology, 
      Queensland Children's Hospital, South Brisbane, Queensland, Australia.
FAU - Le Cao, Kim-Anh
AU  - Le Cao KA
AD  - The University of Queensland, Diamantina Institute, Translational Research 
      Institute, Brisbane, Queensland, Australia.
AD  - The University of Melbourne, Melbourne Integrative Genomics and School of 
      Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, 
      Australia.
FAU - Thomas, Ranjeny
AU  - Thomas R
AD  - The University of Queensland, Diamantina Institute, Translational Research 
      Institute, Brisbane, Queensland, Australia.
FAU - Harris, Mark
AU  - Harris M
AD  - The University of Queensland, Diamantina Institute, Translational Research 
      Institute, Brisbane, Queensland, Australia.
AD  - Queensland Children's Hospital, Department of Paediatric Endocrinology, 
      Queensland Children's Hospital, South Brisbane, Queensland, Australia.
LA  - eng
GR  - 3-PDF-2016-198-A-N/JDRF/Juvenile Diabetes Research Foundation/United States
GR  - 1-PNF-2014-143-A-V/JDRF/Juvenile Diabetes Research Foundation/United States
GR  - 1071922/National Health and Medical Research Council/International
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190108
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (C-Peptide)
RN  - S4M959U2IJ (teplizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - C-Peptide/*metabolism
MH  - Child
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 1/*diagnosis/*drug therapy/epidemiology/*metabolism
MH  - Female
MH  - Humans
MH  - Insulin Secretion/physiology
MH  - Insulin-Secreting Cells/pathology/*physiology
MH  - Male
MH  - *Models, Biological
MH  - Prognosis
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - C-peptide
OT  - beta cell function
OT  - partial remission
OT  - type 1 diabetes
EDAT- 2018/12/18 06:00
MHDA- 2019/09/03 06:00
CRDT- 2018/12/18 06:00
PHST- 2018/04/23 00:00 [received]
PHST- 2018/11/28 00:00 [revised]
PHST- 2018/11/29 00:00 [accepted]
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2019/09/03 06:00 [medline]
PHST- 2018/12/18 06:00 [entrez]
AID - 10.1111/pedi.12808 [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2019 Mar;20(2):166-171. doi: 10.1111/pedi.12808. Epub 2019 Jan 
      8.